(SNDX) Syndax Pharmaceuticals - Ratings and Ratios

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company specializing in the development of innovative therapies for cancer treatment. The companys pipeline is centered around targeted and epigenetic therapies, with a strong focus on addressing unmet needs in hematological malignancies and solid tumors. Its lead product candidate, Revuforj (revumenib), is a menin inhibitor designed to target relapsed or refractory (R/R) acute leukemia, including acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and KMT2Ar acute leukemia. Revumenib is also being investigated in combination with standard-of-care agents for mNPM1 AML and in metastatic colorectal cancer. Another key candidate, Niktimvo (axatilimab-csfr), is a colony-stimulating factor-1 receptor (CSF-1R) blocking antibody being developed to treat chronic graft-versus-host disease (cGVHD), a significant complication of stem cell transplantation. Additionally, the company is advancing axatilimab for idiopathic pulmonary fibrosis and Entinostat, a Class 1 HDAC inhibitor, which is being explored in combination with other therapies for solid tumors. Syndax has entered into a licensing agreement with Eddingpharm International Company Limited for the development and commercialization of Entinostat in certain territories. The company was founded in 2005 and is headquartered in New York, New York.

Based on the provided and , here is a 3-month forecast:

- Technical Outlook: The stock is currently trading at $13.73, below its 200-day SMA of $16.50, indicating potential short-term weakness. The 20-day and 50-day SMAs are $12.22 and $13.17, respectively, suggesting a possible sideways or slightly bearish trend. Average volume of 1.64 million shares over 20 days and an ATR of 0.89 indicate moderate volatility. - Fundamental Outlook: With a market cap of $1.18 billion and a P/S ratio of 49.78, the company is valued at a premium relative to its peers, reflecting investor confidence in its pipeline. The absence of P/E and RoE metrics highlights the companys focus on growth and clinical progress over near-term profitability. The P/B ratio of 4.09 suggests that investors anticipate significant growth in book value.